【レポートの概要（一部）】
1 Table of Contents
1 Table of Contents 11
1.1 List of Tables 19
1.2 List of Figures 26
2 Introduction 28
2.1 Catalyst 28
2.2 Related Reports 29
2.3 Upcoming Related Reports 29
3 Disease Overview 30
3.1 Etiology 30
3.1.1 Viral Lifecycle 30
3.2 Pathophysiology 33
3.3 Staging and Symptoms 34
3.3.1 Primary or Acute Infection 34
3.3.2 Chronic Infection 35
3.3.3 Advanced Infection/AIDS 35
3.4 Prognosis 37
3.5 Quality of Life 37
4 Epidemiology 39
4.1 Disease Background 39
4.2 Risk Factors and Comorbidities 39
4.3 Global Trends 41
4.3.1 US 42
4.3.2 5EU 42
4.3.3 Brazil, China, and Japan 43
4.4 Forecast Methodology 44
4.4.1 Sources Used 45
4.4.2 Sources Not Used 55
4.4.3 Forecast Assumptions and Methods 56
4.5 Epidemiological Forecast for HIV in the 8MM (2013-2023) 62
4.5.1 Total Prevalent Cases of HIV 62
4.5.2 Age-Specific Total Prevalent Cases of HIV 64
4.5.3 Sex-Specific Total Prevalent Cases of HIV 66
4.5.4 Age-Standardized Total Prevalence of HIV 68
4.5.5 HIV Cases Treated with ART 69
4.5.6 Cases of HIV in Pregnant Women 70
4.6 Epidemiological Forecast for HIV in Japan (2013-2023) 71
4.6.1 20-Year Diagnosed Prevalent Cases of HIV 71
4.6.2 Age-Specific 20-Year Diagnosed Prevalent Cases of HIV 72
4.6.3 Sex-Specific 20-Year Diagnosed Prevalent Cases of HIV 73
4.6.4 Age-Standardized 20-Year Diagnosed Prevalence of HIV 74
4.6.5 HIV Cases Treated with ART 75
4.6.6 Cases of HIV in Pregnant Women 76
4.7 Discussion 76
4.7.1 Epidemiological Forecast Insight 76
4.7.2 Limitations of the Analysis 77
4.7.3 Strengths of the Analysis 78
5 Disease Management 79
5.1 Diagnosis and Treatment Overview 79
5.1.1 Screening and Diagnosis 79
5.1.2 Treatment Guidelines and Leading Prescribed Drugs 80
5.1.3 Clinical Practice 82
5.2 US 92
5.2.1 Screening and Diagnosis 94
5.2.2 Clinical Practice 95
5.3 5EU 97
5.3.1 Screening and Diagnosis 98
5.3.2 Clinical Practice 99
5.4 Japan 103
5.4.1 Screening and Diagnosis 104
5.4.2 Clinical Practice 104
5.5 Brazil 107
5.5.1 Screening and Diagnosis 107
5.5.2 Clinical Practice 108
5.6 China 111
5.6.1 Screening and Diagnosis 111
5.6.2 Clinical Practice 112
6 Competitive Assessment 115
6.1 Overview 115
6.2 Product Profiles – Major Brands, Single-Tablet Regimens (STRs) 118
6.2.1 Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) 118
6.2.2 Complera (emtricitabine/TDF/rilpivirine) 124
6.2.3 Stribild (elvitegravir/cobicistat/TDF/emtricitabine) 131
6.2.4 Triumeq (dolutegravir/abacavir/lamivudine) 139
6.3 Product Profiles – Major Brands, Fixed-Dose Combinations 147
6.3.1 Truvada (TDF/emtricitabine) 147
6.3.2 Epzicom (abacavir/lamivudine) 153
6.3.3 Kaletra (lopinavir/ritonavir) 158
6.3.4 Prezcobix (darunavir/cobicistat) 164
6.3.5 Evotaz (atazanavir sulfate/cobicistat) 169
6.4 Product Profiles – Major Brands, Protease Inhibitors 175
6.4.1 Reyataz (atazanavir) 175
6.4.2 Prezista (darunavir) 180
6.5 Product Profiles – Major Brands, Integrase Inhibitors 185
6.5.1 Isentress (raltegravir) 185
6.5.2 Tivicay (dolutegravir) 191
6.5.3 Vitekta (elvitegravir) 199
6.6 Product Profiles – Major Brands, Pharmacokinetic Enhancers 205
6.6.1 Norvir (ritonavir) 205
6.6.2 Tybost (cobicistat) 209
6.7 Other Therapeutic Classes 215
6.7.1 Entry Inhibitors 215
7 Unmet Need and Opportunity 216
7.1 Overview 216
7.2 Therapies with Improved Safety and Tolerability Profiles 218
7.2.1 Unmet Need 218
7.2.2 Gap Analysis 219
7.2.3 Opportunity 220
7.3 Simplified PI-Based ART Regimens with a Reduced Pill Burden 221
7.3.1 Unmet Need 221
7.3.2 Gap Analysis 222
7.3.3 Opportunity 223
7.4 Enhanced Public Awareness Initiatives Focused on Minimizing the Stigma Associated with HIV 224
7.4.1 Unmet Need 224
7.4.2 Gap Analysis 225
7.4.3 Opportunity 226
7.5 Improved Physician Education Tools That Emphasize the Importance of Early Testing and Diagnosis 226
7.5.1 Unmet Need 226
7.5.2 Gap Analysis 228
7.5.3 Opportunity 228
7.6 Safe and Efficacious Therapies for Patients with Drug-Resistant HIV Strains 228
7.6.1 Unmet Need 228
7.6.2 Gap Analysis 229
7.6.3 Opportunity 230
7.7 Long-Acting Regimens That Require Less Frequent Administration 230
7.7.1 Unmet Need 230
7.7.2 Gap Analysis 231
7.7.3 Opportunity 232
7.8 Improved Access to Treatment 232
7.8.1 Unmet Need 232
7.8.2 Gap Analysis 233
7.8.3 Opportunity 233
7.9 Progress Towards a Functional Cure 234
7.9.1 Unmet Need 234
7.9.2 Gap Analysis 234
7.9.3 Opportunity 235
8 Pipeline Assessment 236
8.1 Overview 236
8.2 Clinical Trial Mapping 237
8.2.1 Clinical Trials by Country 237
8.3 Promising Drugs in Late-Stage Clinical Development 238
8.3.1 Quad 2 (elvitegravir/cobicistat/emtricitabine/TAF) 241
8.3.2 Darunavir/Cobicistat/Emtricitabine/TAF 252
8.3.3 Emtricitabine/TAF 261
8.3.4 Dutrebis (raltegravir/lamivudine) 269
8.3.5 Doravirine (MK-1439) 276
8.4 Promising Drugs in Early-Stage Clinical Development 284
8.5 Other Drugs in Clinical Development 287
9 Current and Future Players 289
9.1 Overview 289
9.2 Trends in Corporate Strategy 291
9.3 Company Profiles 293
9.3.1 Gilead Sciences 293
9.3.2 ViiV Healthcare 298
9.3.3 AbbVie 303
9.3.4 Merck & Co. 306
9.3.5 Janssen 310
9.3.6 Bristol-Myers Squibb 314
9.3.7 Japan Tobacco 319
9.3.8 Avexa 322
9.3.9 TaiMed Biologics 325
9.3.10 Tobira Therapeutics 327
10 Market Outlook 331
10.1 Global Markets 331
10.1.1 Forecast 331
10.1.2 Drivers and Barriers – Global Issues 337
10.2 United States 339
10.2.1 Forecast 339
10.2.2 Key Events 345
10.2.3 Drivers and Barriers 346
10.3 5EU 348
10.3.1 Forecast 348
10.3.2 Key Events 356
10.3.3 Drivers and Barriers 357
10.4 Japan 363
10.4.1 Forecast 363
10.4.2 Key Events 368
10.4.3 Drivers and Barriers 370
10.5 Brazil 372
10.5.1 Forecast 372
10.5.2 Key Events 377
10.5.3 Drivers and Barriers 378
10.6 China 380
10.6.1 Forecast 380
10.6.2 Key Events 384
10.6.3 Drivers and Barriers 385
11 Appendix 388
11.1 Bibliography 388
11.2 Abbreviations 422
11.3 Methodology 429
11.4 Forecasting Methodology 429
11.4.1 Total Prevalent Cases of HIV 429
11.4.2 20-Year Diagnosed Prevalent Cases of HIV 429
11.4.3 HIV Cases Treated with ART 430
11.4.4 Drugs Included in Each Therapeutic Class 431
11.4.5 Launch and Patent Expiry Dates 432
11.4.6 General Pricing Assumptions 433
11.4.7 Individual Drug Assumptions 435
11.4.8 Generic Erosion 453
11.4.9 Pricing of Pipeline Agents 453
11.5 Primary Research – KOLs Interviewed for This Report 455
11.6 Primary Research – Prescriber Survey 457
11.7 About the Authors 458
11.7.1 Analyst 458
11.7.2 Epidemiologists 458
11.7.3 Therapy Area Director 458
11.7.4 Global Director of Therapy Analysis and Epidemiology 459
11.7.5 Global Head of Healthcare 459
11.8 About GlobalData 460
11.9 Disclaimer 460
【レポート販売概要】
■ タイトル：HIV治療薬の世界市場予測および分析■ 英文：PharmaPoint: Human Immunodeficiency Virus (HIV) - Global Drug Forecast and Market Analysis to 2023
■ 発行日：2015年9月9日
■ 調査会社：GlobalData
■ 商品コード：GDHC94PIDR
■ 調査対象地域：グローバル
- 化学療法に伴う貧血：世界の臨床試験レビュー（2014年上半期）Chemotherapy Induced Anemia Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Chemotherapy Induced Anemia Global Clinical Trials Review, H1, 2014" provides data on the Chemotherapy Induced Anemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Chemotherapy Induced Anemia. It includes an overview of t …
- パッチ管理の世界市場予測（～2024年）The patch management market is expected to grow at a CAGR of 10.7% during the forecast period owing to the increasing vulnerabilities to promote patch management solutions and growing demand for up-to-date Operating Systems (OS)/applications to drive the patch management market during the forecast periodThe global patch management market size is expected to grow from USD 589 million in 2019 to USD …
- 世界の前立腺がん治療薬市場予測と分析PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2022 Summary GlobalData's report "PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2022", provides comprehensive information on prostate cancer therapeutics, highlighting the treatment guidelines and identifies and analyses the key trends shaping and driving the market. The report analyses the trea …
- 世界のスマートトランスポーテーション市場（2012-2016）TechNavio's analysts forecast Global Smart Transportation market to grow at a CAGR of 25.6 percent over the period 2012-2016. One of the key factors contributing to this growth is the growing Global Smart Cities market. The Global Smart Transportation market has also been witnessing an increased investment in traffic management systems. However, high maintenance costs could pose a challenge to the …
- モバイルアプリテストサービスの世界市場2017-2021About Mobile Application Testing (MAT) Services Software testers face many challenges while developing innovative and error-free software products and applications. They require IT solutions that can minimize the cost of testing services and enhance the quality of software. Rapid changes in technology and increasing mobility solutions compel software developers to consider testing as an important …
- 電動スクーターの世界市場分析：製品別（レトロ、起立/自己平衡型、折りたたみ）、電池別（密閉鉛酸、NiMH、リチウムイオン）、電圧別（24V、36V、48V）、セグメント予測、2014 – 2024The global electric scooters market is expected to reach USD 38.57 billion by 2024, according to a new report by Grand View Research, Inc. As the automotive industry is growing, the uncertainty over the adoption of electric scooters is gaining importance as manufacturers are developing strategies to realize the full potential of the evolving electric two-wheeler industry. The introduction of home …
- 2014年戦略提言：Legionella診断検査市場The report presents a detailed analysis of the Legionella diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Legionella definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: - Hospitals - Co …
- Nasopharyngitis (Common Cold)：グローバル臨床試験レビューH2, 2013Nasopharyngitis (Common Cold) Global Clinical Trials Review, H2, 2013 Summary GlobalData's clinical trial report, “Nasopharyngitis (Common Cold) Global Clinical Trials Review, H2, 2013" provides data on the Nasopharyngitis (Common Cold) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Nasopharyngitis (Common Cold). It includes an overv …
- ヒカマの世界市場2018-2022About this market One of the growth drivers of the global jicama market is the increasing awareness among consumers about the health benefits through the consumption of jicama. This increases the demand for jicama globally. Jicama helps in maintaining blood pressure. It is a rich source of potassium. which helps in reducing the tension on blood vessels and arteries. thereby lowering stress on the …
- インフルエンザ診断の世界市場：テストタイプ別（RIDT、RT-PCR、細胞培養）、最終用途別（病院、ラボ、ポイントオブケア検査（POCT））、地域別予測Global Influenza diagnostics Market to reach USD 3.6 billion by 2025. Global Influenza diagnostics Market valued approximately USD 1.91 billion in 2016 is anticipated to grow with a healthy growth rate of more than 6.4% over the forecast period 2017-2025. Influenza, which is commonly called the flu is an infectious disease of the upper respiratory system caused by the influenza virus. The seasonal …
- MDU Resources Group, Inc.：石油・ガスの開発・生産動向及びコスト分析– Q4, 2012MDU Resources Group, Inc. Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2012 Summary MDU Resources Group, Inc. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essentia …
- 米国のスマート教育市場2016-2020About Smart Education A technology-driven education system like the smart education architecture includes information, resources, and professional development opportunities to support institutions in imparting education to students in a digitally rich environment. In this system, traditional teaching methodologies are transformed to improve the learning process and knowledge delivery. The smart ed …
- グリーンビルディングの世界市場As green building techniques lead to a much lower level of greenhouse gas emissions, thus the global green building market is witnessing a strong growth in recent years on the back of rising awareness concerning global warming and climate change. The governments in different countries are also taking various regulatory measures to expand the green building market. As per our latest research report …
- 世界のオイルシェール市場分析：Analyzing the Global Oil Shale MarketThe term oil shale generally refers to any sedimentary rock that contains solid bituminous materials (called kerogen) that are released as petroleum-like liquids when the rock is heated in the chemical process of pyrolysis. Oil shale was formed millions of years ago by deposition of silt and organic debris on lake beds and sea bottoms. Over long periods of time, heat and pressure transformed the m …
- 膜用化学品の世界市場：インサイト、市場機会、市場シェア、市場予測The global membrane chemical market is estimated to register robust growth in 2016- 2022 and is expected to grow at CAGR of 8.5% during 2016-2022. The Membrane chemical market is segmented on the basis of product, end user and geography. The end user segment is further segmented into Chemicals, Desalination, Food and Beverage, Paper & Pulp, Power, Waste water treatment. However, in the end user se …
